Pfizer Begins Study of Omicron Specific Covid Vaccine

preview_player
Показать описание
Pfizer Inc. said it is starting a study of a Covid-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

The New York-based drugmaker and its German partner, BioNTech SE, said in a statement on Tuesday that they had enrolled the first participants in a 1,420-person clinical trial that will evaluate the shot’s ability to prompt an immune response in healthy adults age 18 to 55. The study will also examine the shot’s safety and potential side effects.

Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

Connect with us on…
Рекомендации по теме
Комментарии
Автор

ask fizer to prove it has brains - they should produce 3 negative no brain test

AdvKapatkarS